---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-24-000036"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:13:56.810731+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AbbVie Q3 EPS $3.00 adjusted (+1.7%), revenue $14.46B (+3.8%); raises 2024 guidance, increases dividend 5.8%

## Summary
- Adjusted diluted EPS $3.00, up 1.7% YoY; GAAP EPS $0.88, down 12.0%.
- Revenue $14.460B, +3.8% reported (+4.9% operational); Immunology $7.046B (+3.9%) led by Skyrizi (+50.8%) and Rinvoq (+45.3%).
- Raises 2024 adjusted EPS guidance to $10.90-$10.94 from $10.67-$10.87.
- Increases quarterly dividend 5.8% to $1.64/share, payable Feb 14, 2025 to holders of record Jan 15, 2025.
- Completed acquisition of Cerevel, adding pipeline of complementary neuroscience assets.

## SEC filing metadata
- accession: 0001551152-24-000036
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000036/0001551152-24-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000036/abbv-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-24-000036
- JSON: https://secwatch.observer/filing/0001551152-24-000036.json
- Plain text: https://secwatch.observer/filing/0001551152-24-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.